Pentamidine is active in vitro against Fusarium species.
Fusariosis is an emerging opportunistic mycosis against which currently used antifungals have limited activity. Here, we investigated the in vitro activities of pentamidine (PNT) against 10 clinical isolates of Fusarium species (five Fusarium solani isolates and five non-F. solani isolates) by using the National Committee for Clinical Laboratory Standards microdilution method in three different media (RPMI, RPMI-2, and a yeast nitrogen base medium), disk diffusion testing, and viability dye staining. PNT had significant activities against all 10 Fusarium isolates. Non-F. solani isolates were more susceptible than F. solani isolates (P < 0.05). Additionally, PNT was fungicidal against all non-F. solani isolates, whereas it had fungistatic effects against four of the five F. solani isolates. PNT also exhibited greater activity against conidial than against hyphal development of the fungus. This fungicidal activity against non-F. solani Fusarium isolates was confirmed microscopically after staining of PNT-treated Fusarium oxysporum hyphae with the fluorescent viability dyes 5,(6)-carboxyfluorescein diacetate (CFDA) and bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC). The MICs at which 50% of the isolates were inhibited (2 micro g/ml for non-F. solani isolates and 4 micro g/ml for F. solani isolates) and the minimum fungicidal concentration at which 50% of the isolates were killed (8 micro g/ml for non-F. solani isolates) were much lower than the PNT tissue concentrations previously reported in humans using conventional daily intravenous PNT dosing. Finally, PNT was more active against Fusarium isolates in a hypoxic environment of in vitro growth (P < 0.05). This finding may be clinically significant, because Fusarium, an angiotropic mold, causes tissue infarcts with resultant low tissue perfusion. Our findings suggest that PNT may have a role in the management of Fusarium infections. Future in vivo studies are needed to verify these in vitro findings.
D000332:Aerobiosis; D000693:Anaerobiosis; D000935:Antifungal Agents / Q000494:pharmacology*; D003124:Colorimetry / Q000379:methods; D003470:Culture Media; D005670:Fusarium / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D025301:Hyphae / Q000187:drug effects / Q000254:growth & development / Q000648:ultrastructure; D008826:Microbial Sensitivity Tests / Q000379:methods; D008856:Microscopy, Fluorescence; D010419:Pentamidine / Q000494:pharmacology*
D000935:Antifungal Agents; D003470:Culture Media; D010419:Pentamidine